IBDEI0C6 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5779,2)
 ;;=^29802
 ;;^UTILITY(U,$J,358.3,5780,0)
 ;;=253.5^^49^519^3
 ;;^UTILITY(U,$J,358.3,5780,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5780,1,4,0)
 ;;=4^DIABETES INSIPIDUS
 ;;^UTILITY(U,$J,358.3,5780,1,5,0)
 ;;=5^253.5
 ;;^UTILITY(U,$J,358.3,5780,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,5781,0)
 ;;=253.8^^49^519^4
 ;;^UTILITY(U,$J,358.3,5781,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5781,1,4,0)
 ;;=4^EMPTY SELLA SYNDROME
 ;;^UTILITY(U,$J,358.3,5781,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,5781,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,5782,0)
 ;;=253.1^^49^519^5
 ;;^UTILITY(U,$J,358.3,5782,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5782,1,4,0)
 ;;=4^HYPERPROLACTINEMIA
 ;;^UTILITY(U,$J,358.3,5782,1,5,0)
 ;;=5^253.1
 ;;^UTILITY(U,$J,358.3,5782,2)
 ;;=^87260
 ;;^UTILITY(U,$J,358.3,5783,0)
 ;;=253.2^^49^519^6
 ;;^UTILITY(U,$J,358.3,5783,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5783,1,4,0)
 ;;=4^PANHYPOPITUITARISM
 ;;^UTILITY(U,$J,358.3,5783,1,5,0)
 ;;=5^253.2
 ;;^UTILITY(U,$J,358.3,5783,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,5784,0)
 ;;=227.3^^49^519^7
 ;;^UTILITY(U,$J,358.3,5784,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5784,1,4,0)
 ;;=4^PITUITARY TUMOR,BENIGN
 ;;^UTILITY(U,$J,358.3,5784,1,5,0)
 ;;=5^227.3
 ;;^UTILITY(U,$J,358.3,5784,2)
 ;;=^267690
 ;;^UTILITY(U,$J,358.3,5785,0)
 ;;=253.8^^49^519^8
 ;;^UTILITY(U,$J,358.3,5785,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5785,1,4,0)
 ;;=4^RATHKE'S CYST
 ;;^UTILITY(U,$J,358.3,5785,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,5785,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,5786,0)
 ;;=253.4^^49^520^3
 ;;^UTILITY(U,$J,358.3,5786,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5786,1,4,0)
 ;;=4^ANTER PITUITARY DIS NEC
 ;;^UTILITY(U,$J,358.3,5786,1,5,0)
 ;;=5^253.4
 ;;^UTILITY(U,$J,358.3,5786,2)
 ;;=^267862
 ;;^UTILITY(U,$J,358.3,5787,0)
 ;;=258.9^^49^520^14
 ;;^UTILITY(U,$J,358.3,5787,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5787,1,4,0)
 ;;=4^POLYGLANDUL DYSFUNC NOS
 ;;^UTILITY(U,$J,358.3,5787,1,5,0)
 ;;=5^258.9
 ;;^UTILITY(U,$J,358.3,5787,2)
 ;;=^267894
 ;;^UTILITY(U,$J,358.3,5788,0)
 ;;=258.1^^49^520^15
 ;;^UTILITY(U,$J,358.3,5788,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5788,1,4,0)
 ;;=4^POLYGLANDULAR FAILURE
 ;;^UTILITY(U,$J,358.3,5788,1,5,0)
 ;;=5^258.1
 ;;^UTILITY(U,$J,358.3,5788,2)
 ;;=^267892
 ;;^UTILITY(U,$J,358.3,5789,0)
 ;;=626.0^^49^520^1
 ;;^UTILITY(U,$J,358.3,5789,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5789,1,4,0)
 ;;=4^AMENORRHEA
 ;;^UTILITY(U,$J,358.3,5789,1,5,0)
 ;;=5^626.0
 ;;^UTILITY(U,$J,358.3,5789,2)
 ;;=^5871
 ;;^UTILITY(U,$J,358.3,5790,0)
 ;;=628.0^^49^520^2
 ;;^UTILITY(U,$J,358.3,5790,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5790,1,4,0)
 ;;=4^ANOVULATION,INFERTILITY
 ;;^UTILITY(U,$J,358.3,5790,1,5,0)
 ;;=5^628.0
 ;;^UTILITY(U,$J,358.3,5790,2)
 ;;=^270583
 ;;^UTILITY(U,$J,358.3,5791,0)
 ;;=626.5^^49^520^12
 ;;^UTILITY(U,$J,358.3,5791,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5791,1,4,0)
 ;;=4^OVULATION BLEEDING
 ;;^UTILITY(U,$J,358.3,5791,1,5,0)
 ;;=5^626.5
 ;;^UTILITY(U,$J,358.3,5791,2)
 ;;=^270570
 ;;^UTILITY(U,$J,358.3,5792,0)
 ;;=627.1^^49^520^16
 ;;^UTILITY(U,$J,358.3,5792,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5792,1,4,0)
 ;;=4^POSTMENOPAUSAL BLEEDING
 ;;^UTILITY(U,$J,358.3,5792,1,5,0)
 ;;=5^627.1
 ;;^UTILITY(U,$J,358.3,5792,2)
 ;;=^97040
 ;;^UTILITY(U,$J,358.3,5793,0)
 ;;=617.9^^49^520^4
 ;;^UTILITY(U,$J,358.3,5793,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5793,1,4,0)
 ;;=4^ENDOMETRIOSIS NOS
 ;;^UTILITY(U,$J,358.3,5793,1,5,0)
 ;;=5^617.9
 ;;^UTILITY(U,$J,358.3,5793,2)
 ;;=^40463
